Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicyNew EASL Studio Episode on Rifaximin & Hepatic Encephalopathy now online
Now online: You can watch and/or listen online to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 November 2026. It features MICROB-PREDICT's coordinator Jonel Trebicka as well as consortium members Rajiv Jalan & Vishal C. Patel as speakers and Debbie Shawcross as moderator. The session explores the clinical value of rifaximin in the management of hepatic encephalopathy while addressing the growing concerns surrounding antimicrobial resistance.
More newsALB-TRIAL celebrates 50% enrollment milestone
The ALB-TRIAL, MICROB-PREDICT's clinical study, has reached the halfway milestone: 50% of the planned 240 patients are now enrolled! Congratulations to everyone involved. Recruitment has taken place at 14 active centres across seven European countries, marking a major step forward for the trial. The ALB-TRIAL is a European, double-blinded, placebo-controlled clinical study. Its goal is to explore whether a novel biomarker can help predict which patients with cirrhosis and ascites benefit most from long-term human albumin infusions.
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news